Advertisement Pharmaceutical Business review - Page 293 of 5269 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 16, 2026

Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for patients with extensive-stage small cell lung cancer (ES-SCLC) and other neuroendocrine carcinomas (NECs).

Continue
Obrixtamig is an investigational bispecific DLL3 engager that targets DLL3-expressing cancer cells in SCLC and NECs. Credit: CI Photos / Shutterstock.com.
April 16, 2026

Nucleai and Sirona Dx to provide new proteomics solution for pharma companies

Nucleai uses AI-based spatial analytics, starting with feature extraction and progressing through biomarker discovery and interpretation. Credit: tilialucida / Shutterstock.com.
April 15, 2026

Adcendo secures $75m in Series C funding for ADC development

The funding will also support ADCE-D01 studies in soft tissue sarcoma and mesenchymal cancers. Credit: Sai Thaw Kyar / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Lilly to acquire CrossBridge Bio for up to $300m
  2. Travere Therapeutics gains FDA approval for sparsentan in FSGS
  3. MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
  4. FDA issues complete response letter to Replimune’s RP1 for melanoma
  5. Telix and Regeneron to co-develop radiopharmaceutical therapies

PRESS RELEASES

SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Pharmaceutical Business Review
Christian Mias to Succeed Andreas Reisse as CEO of SCHOTT Pharma
Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography